EVEROLIMUS
TARGETED AGENTS
RADIANT-4 GASTROINTESTINAL TRACT AND UNKNOWN PRIMARY SUBGROUP
ANALYSIS (N=175)
PFS treatment effect for patient primary tumor site per central review
Singh S, et al. Neuroendocrinology 2017
mPFS GI = 13,1 vs 5,4 months (HR 0,56; 95%CI 0,37-0,84)
mPFS CUP = 13,6 vs 7,5 months (HR 0,60; 95%CI 0,24-1,51)